261 related articles for article (PubMed ID: 36662305)
1. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
2. Early evaluation of CAR-T cell therapy response in R/R DLBCL patients using
Kitajima K; Yokoyama H; Wada R; Tamaki Y; Yoshihara K; Kaida K; Yoshihara S; Yamakado K
Hell J Nucl Med; 2024; 27(1):8-15. PubMed ID: 38629814
[TBL] [Abstract][Full Text] [Related]
3. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
4. [
Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
Iacoboni G; Simó M; Villacampa G; Catalá E; Carpio C; Díaz-Lagares C; Vidal-Jordana Á; Bobillo S; Marín-Niebla A; Pérez A; Jiménez M; Abrisqueta P; Bosch F; Barba P
Ann Hematol; 2021 Sep; 100(9):2303-2310. PubMed ID: 34236497
[TBL] [Abstract][Full Text] [Related]
7.
Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
[TBL] [Abstract][Full Text] [Related]
8. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
9. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11.
Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers.
Mussetti A; Fabbri N; Sureda A
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):357-363. PubMed ID: 38066912
[TBL] [Abstract][Full Text] [Related]
13. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
15. Conventional and novel [
Leithner D; Flynn JR; Devlin SM; Mauguen A; Fei T; Zeng S; Zheng J; Imber BS; Hubbeling H; Mayerhoefer ME; Bedmutha A; Luttwak E; Corona M; Dahi PB; Luna de Abia A; Landego I; Lin RJ; Palomba ML; Scordo M; Park JH; Tomas AA; Salles G; Lafontaine D; Michaud L; Shah GL; Perales MA; Shouval R; Schöder H
J Hematol Oncol; 2024 Apr; 17(1):21. PubMed ID: 38649972
[TBL] [Abstract][Full Text] [Related]
16. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Breen WG; Hathcock MA; Young JR; Kowalchuk RO; Bansal R; Khurana A; Bennani NN; Paludo J; Villasboas Bisneto JC; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
J Hematol Oncol; 2022 Mar; 15(1):36. PubMed ID: 35346315
[TBL] [Abstract][Full Text] [Related]
18. Baseline [
Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
[TBL] [Abstract][Full Text] [Related]
19. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
[TBL] [Abstract][Full Text] [Related]
20. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]